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We monitored the severe acute respiratory syndrome coronavirus 2 antibody
response in seven dogs and two cats by using two multispecies ELISA tests, plaque
reduction neutralisation test and virus neutralization. SARS-CoV-2 neutralizing anti-
bodies in pets persisted up to 10months since the first positive testing, thus replicating
observations in COVID-19 human patients.
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Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has
been found to infect a plethora of mammals, including dogs and cats
(Decaro, Balboni, et al., 2021). There are some reports of SARS-CoV-2
active infection and/or detection of specific antibodies in domestic car-
nivores (Colitti et al., 2021; Decaro, Vaccari, et al., 2021; Hamer et al.,
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2021; Patterson et al., 2020). While several studies have found that
SARS-CoV-2 neutralizing antibodies can persist from 6–8 months to
more than 12 months in humans (Chia et al., 2021; Dispinseri et al.,
2021; Knies et al., 2021; Sonnleitner et al., 2021), no data are available
about the persistence of the antibody response in dogs and cats. Here,
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Dog 1 9 Yes 1 01 Apr 2020 Neg Neg 1:40 1:20 ≥10
2 29 Jul 2020 Neg Neg <1:20 <1:10
3 08 Feb 2021 Neg Neg <1:20 1:10
Dog 2 8 Yes 1 24 Apr 2020 Neg Neg <1:20 <1:10 ≥9
2 25 Jul 2020 Neg Neg 1:40 <1:10
3 22 Jan 2021 Neg Neg <1:20 1:10
Dog 3 11 Yes 1 24 Apr 2020 Neg Neg 1:40 1:10 <3
2 27 Jul 2020 Neg Neg <1:20 <1:10
3 22 Jan 2021 Neg Neg <1:20 <1:10
Dog 4 11 Yes 1 24 Apr 2020 Neg Neg 1:20 <1:10 <3
2 25 Jul 2020 Neg Neg <1:20 <1:10
3 22 Jan 2021 Neg Neg <1:20 <1:10
Dog 5 5 Yes 1 05May 2020 Pos (209%) Pos (57%) 1:160 1:160 ≥9
2 07 Aug 2020 Pos (263%) Pos (76%) 1:320 1:10
3 06 Feb 2021 Pos (196%) Pos (47%) 1:80 1:40
Dog 6 1.5 Yes 1 25May 2020 ND ND 1:80 1:80 ≥8
2 30 Jul 2020 Neg Neg 1:80 1:20
3 27 Jan 2021 Neg Neg 1:40 1:40
Dog 7 1.5 Yes 1 25Nov 2020 Neg Pos (23%) 1:80 1:10 ≥3
2 12Dec 2020 Neg Neg 1:80 1:20
3 28 Feb 2021 Neg Pos (59%) 1:80 1:40
Cat 1 17 No 1 12May 2020 Pos (152%) Pos (30%) 1:80 1:20 ≥8
2 28 Jul 2020 Neg Neg 1:20 <1:10
3 26 Jan 2021 Neg Neg 1:20 1:40
Cat 2 7 Yes 1 03 Apr 2020 Pos (237%) Neg 1:160 1:40 ≥10
2 30 Jul 2020 Pos (>QR) Pos (123%) 1:640 1:80
3 08 Feb 2021 Pos (>QR) Pos (138%) 1:160 1:80
Abbreviations: ELISA, enzyme-linked immunosorbent assay; ND, not done; Neg, negative; Pos, positive; PRNT80, plaque reduction neutralization test; >QR,
above the quantification range; VN, virus neutralization.
aValues in brackets represent the ratio between the optical densities of the tested serum and the positive control (cut-off value= 50%).
bValues in brackets represent the ratio between the optical densities of the tested serum and the positive control (cut-off value= 20%).
cAntibody titre is expressed as the highest serum dilutionwith 80% reduction in plaques in inoculated VERO-E6 cells
compared to the control, with 1:20 being the lowest serum dilution tested.
dAntibody titre is expressed as the highest serum dilution giving 100% reduction of cytopathic effect in inoculated VERO-E6 cells, with 1:10 being the lowest
serum dilution tested.
we report the results of a longitudinal study in SARS-CoV-2 seroposi-
tive pets demonstrating the persistence of neutralizing antibodies for
up to 10months in some animals.
The pets included seven dogs and two cats, which had SARS-CoV-
2 neutralizing antibodies according to previous studies (Decaro, Vac-
cari, et al., 2021; Patterson et al., 2020) or at a first screening (Table 1).
The age of the tested animals ranged from 1.5 to 11 years and from
7 to 17 years for dogs and cats, respectively. All seven dogs and one
of two cats were from COVID-19 positive households, but none of the
sampled animals had developed COVID-19 clinical signs. Only one dog
(Dog 7) had been found to shed SARS-CoV-2 RNA by real-time PCR
(Decaro, Vaccari, et al., 2021). For pets living in COVID-19 households,
sera collection was initially carried out between 7 and 60 days after
SARS-CoV-2 molecular detection in their owners. Sera were collected
at different timepoints according to theowners’ convenience andwere
tested with two commercial multispecies ELISA kits, ID Screen SARS-
CoV-2 Double Antigen Multi-species ELISA (ID.vet, Grabels, France)
and EradikitT COVID19Multispecies (In3Diagnostic, Turin, Italy), with
a plaque reduction neutralization test (PRNT) (Patterson et al., 2020)
and with virus neutralization (VN) (Zhang et al., 2020). The results
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showed that four of seven dogs and two of two cats had SARS-CoV-
2 neutralizing antibodies at 8 months or more after the first positive
testing (Table 1). For one dog that had tested positive for SARS-CoV-
2 by real-time RT-PCR (Decaro, Vaccari, et al., 2021), sera were avail-
able only for the first 3months after infection and displayed antibodies
throughPRNTandVNat all timepoints. The remaining twodogs tested
positive by PRNT and VN only at the first sampling, whichmay account
for a shorter duration of the humoral immunity rather than for an older
infection, since these animalswere infected during the firstwave of the
COVID-19 pandemic (Patterson et al., 2020). A great discrepancy was
observed between serological tests based on ELISA and neutralization
tests. Five dogs that were seropositive by PRNT and/or VN at one or
more time points were completely negative by both commercial ELISA
tests. The dog (Dog 7) that had been found positive for SARS-CoV-2
RNA (Decaro, Vaccari, et al., 2021)was constantly seropositive by both
PRNT and VN, but invariably negative by the ID.vet ELISA and positive
at two out of three time points by the In3Diagnostic ELISA. In contrast,
the discrepancy between PRNT and VN was less evident, being gen-
erally restricted to few sera with low neutralizing antibody titres. The
discrepancy between ELISA and neutralization tests may be related to
a lower sensitivity of ELISA or, alternatively, to a lack of specificity of
neutralization assays. However, the latter hypothesis could be ruled
out since previous experiments have demonstrated that pre-pandemic
sera thatwere antibodypositive for endemic coronaviruses of dogs and
cats test negative by SARS-CoV-2 neutralization assays (Decaro, Vac-
cari, et al., 2021; Patterson et al., 2020; Zhang et al., 2020). The lower
sensitivity of ELISA compared to VNor PRNTmay be due to a different
kinetic between the antibody response raised against the viral nucleo-
protein (the antigen used in both ELISA tests) and that directed against
the spike protein (themain target of neutralizing antibodies).
Interestingly, for Cat 1 there was no evidence for exposure to
COVID-19 positive human patients. Therefore, it is likely that this cat
was infected by an asymptomatic owner with undiagnosed SARS-CoV-
2 infection or, alternatively, it acquired the virus from other infected
people or animals.
Despite the increasing number of reports of SARS-CoV-2 infection
in dogs and cats, no long-term monitoring has been carried out so far
to evaluate the persistence of specific antibodies in pets. To our knowl-
edge, the antibody response in pets has beenmonitored for amaximum
of 2–3 months after infection, displaying relatively stable or increas-
ing titres and no evidence of seroreversion (Hamer et al., 2021). Zhang
et al. (2020) followed two cats for about 4 months, finding that neu-
tralizing antibodies peaked after 10 days from the first sampling and
then decreased to detection limit in 110 days. Our study, which was
conducted using four different serological assays, demonstrates that
similar to humans, dogs and cats may develop a long-term neutralizing
antibody response against SARS-CoV-2. At which extent the presence
of neutralizing antibodies is able to protect these animals from SARS-
CoV-2 reinfection is currently unknown, thus requiring further studies.
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